A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2024 Apr 18

PMID 38637465

Authors

Koshiro Sonomoto

Yoshihisa Fujino

Hiroaki Tanaka

Atsushi Nagayasu

Shingo Nakayamada

Yoshiya Tanaka

Affiliations

Soon will be listed here.

Abstract

Introduction: This study aimed to develop low-cost models using machine learning approaches predicting the achievement of Clinical Disease Activity Index (CDAI) remission 6 months after initiation of tumor necrosis factor inhibitors (TNFi) as primary biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for rheumatoid arthritis (RA).

Methods: Data of patients with RA initiating TNFi as first b/tsDMARD after unsuccessful methotrexate treatment were collected from the FIRST registry (August 2003 to October 2022). Baseline characteristics and 6-month CDAI were collected. The analysis used various machine learning approaches including logistic regression with stepwise variable selection, decision tree, support vector machine, and lasso logistic regression (Lasso), with 48 factors accessible in routine clinical practice for the prediction model. Robustness was ensured by k-fold cross validation.

Results: Among the approaches tested, Lasso showed the advantages in predicting CDAI remission: with a mean area under the curve 0.704, sensitivity 61.7%, and specificity 69.9%. Predicted TNFi responders achieved CDAI remission at an average rate of 53.2%, while only 26.4% of predicted TNFi non-responders achieved remission. Encouragingly, the models generated relied solely on patient-reported outcomes and quantitative parameters, excluding subjective physician input.

Conclusions: While external cohort validation is warranted for broader applicability, this study highlights the potential for a low-cost predictive model to predict CDAI remission following TNFi treatment. The approach of the study using only baseline data and 6-month CDAI measures, suggests the feasibility of establishing regional cohorts to generate low-cost models tailored to specific regions or institutions. This may facilitate the application of regional/in-house precision medicine strategies in RA management.

References

Smolen J, Landewe R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022; 82(1):3-18. DOI: 10.1136/ard-2022-223356. View

Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M . Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication. Mod Rheumatol. 2022; 33(1):21-35. DOI: 10.1093/mr/roac017. View

Ytterberg S, Bhatt D, Mikuls T, Koch G, Fleischmann R, Rivas J . Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386(4):316-326. DOI: 10.1056/NEJMoa2109927. View

Taylor P, Keystone E, van der Heijde D, Weinblatt M, Del Carmen Morales L, Reyes Gonzaga J . Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017; 376(7):652-662. DOI: 10.1056/NEJMoa1608345. View

Fleischmann R, Mysler E, Hall S, Kivitz A, Moots R, Luo Z . Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017; 390(10093):457-468. DOI: 10.1016/S0140-6736(17)31618-5. View

Fleischmann R, Pangan A, Song I, Mysler E, Bessette L, Peterfy C . Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019; 71(11):1788-1800. DOI: 10.1002/art.41032. View

Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon J, Baraf H . Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021; 80(7):848-858. PMC: 8237199. DOI: 10.1136/annrheumdis-2020-219214. View

Wijbrandts C, Tak P . Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc. 2017; 92(7):1129-1143. DOI: 10.1016/j.mayocp.2017.05.009. View

Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P . An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One. 2009; 4(10):e7556. PMC: 2762038. DOI: 10.1371/journal.pone.0007556. View

10.

Toonen E, Gilissen C, Franke B, Kievit W, Eijsbouts A, den Broeder A . Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One. 2012; 7(3):e33199. PMC: 3310059. DOI: 10.1371/journal.pone.0033199. View

11.

Thomson T, Lescarbeau R, Drubin D, Laifenfeld D, de Graaf D, Fryburg D . Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis. BMC Med Genomics. 2015; 8:26. PMC: 4455917. DOI: 10.1186/s12920-015-0100-6. View

12.

Bek S, Bojesen A, Nielsen J, Sode J, Bank S, Vogel U . Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J. 2017; 17(5):403-411. PMC: 5637244. DOI: 10.1038/tpj.2017.26. View

13.

Aterido A, Canete J, Tornero J, Blanco F, Fernandez-Gutierrez B, Perez C . A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis. Front Immunol. 2019; 10:1459. PMC: 6614444. DOI: 10.3389/fimmu.2019.01459. View

14.

Silvagni E, Giollo A, Sakellariou G, Ughi N, DAmico M, Scire C . One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2020; 38(2):181-194. View

15.

Nerviani A, Di Cicco M, Mahto A, Lliso-Ribera G, Rivellese F, Thorborn G . A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients. Front Immunol. 2020; 11:845. PMC: 7214807. DOI: 10.3389/fimmu.2020.00845. View

16.

Tao W, Concepcion A, Vianen M, Marijnissen A, Lafeber F, Radstake T . Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020; 73(2):212-222. PMC: 7898388. DOI: 10.1002/art.41516. View

17.

Humby F, Durez P, Buch M, Lewis M, Rizvi H, Rivellese F . Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021; 397(10271):305-317. PMC: 7829614. DOI: 10.1016/S0140-6736(20)32341-2. View

18.

Ho C, Silva A, Giles J, Bathon J, Solomon D, Liao K . Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. Arthritis Rheumatol. 2021; 73(6):1086-1087. PMC: 8169520. DOI: 10.1002/art.41645. View

19.

Vastesaeger N, Garcia Kutzbach A, Amital H, Pavelka K, Lazaro M, Moots R . Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology (Oxford). 2016; 55(8):1466-76. PMC: 4957672. DOI: 10.1093/rheumatology/kew179. View

20.

Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen J . Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. Semin Arthritis Rheum. 2019; 50(2):276-284. DOI: 10.1016/j.semarthrit.2019.09.005. View